This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

21 Nov 2011

Shire & Shionogi to Co-develop ADHD Drugs

Shire and Shionogi will co-develop and co-market Shire’s ADHD medicines in Japan.

Global specialty biopharmaceutical company Shire and Japan’s Shionogi & Co. have agreed to co-develop and co-commercialize some of Shire’s medicines for the treatment of attention deficit hyperactivity disorder (ADHD).


The agreement comes nearly three years after Shire opened a representative office in Japan, with the goal of stepping up commercialization of its pipeline products in Japan, the world’s second largest biopharmaceutical market.


Upon approval of medicines for Japan, Shionogi will pay a one-time fee and share costs with Shire.


Shire’s drugs for ADHD include Adderall XR, Intuniv, Vyvanse. All t

Related News